Macquarie Group Ltd. lifted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 350.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,408,331 shares of the company’s stock after buying an additional 3,429,448 shares during the period. Macquarie Group Ltd. owned about 0.43% of Teva Pharmaceutical Industries Limited worth $77,587,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. San Francisco Sentry Investment Group CA bought a new position in Teva Pharmaceutical Industries Limited during the second quarter worth about $106,000. Kistler Tiffany Companies LLC lifted its stake in Teva Pharmaceutical Industries Limited by 74.7% during the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after purchasing an additional 1,571 shares during the period. Bronfman E.L. Rothschild L.P. lifted its stake in Teva Pharmaceutical Industries Limited by 2.6% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after purchasing an additional 94 shares during the period. Cutler Capital Management LLC bought a new position in Teva Pharmaceutical Industries Limited during the second quarter worth about $133,000. Finally, Shelter Mutual Insurance Co bought a new position in Teva Pharmaceutical Industries Limited during the second quarter worth about $133,000. Institutional investors and hedge funds own 55.81% of the company’s stock.

TEVA has been the subject of a number of analyst reports. TheStreet cut shares of Teva Pharmaceutical Industries Limited from a “c-” rating to a “d+” rating in a research note on Friday, August 25th. ValuEngine cut shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Evercore ISI set a $38.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a research note on Wednesday, October 25th. Deutsche Bank AG reiterated a “buy” rating and issued a $28.00 target price (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Finally, Cantor Fitzgerald set a $17.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research note on Thursday, October 26th. Seven investment analysts have rated the stock with a sell rating, seventeen have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries Limited has an average rating of “Hold” and an average price target of $21.88.

ILLEGAL ACTIVITY WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/11/19/macquarie-group-ltd-grows-position-in-teva-pharmaceutical-industries-limited-teva.html.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up $1.05 during mid-day trading on Friday, hitting $13.84. 40,790,517 shares of the stock traded hands, compared to its average volume of 29,924,660. Teva Pharmaceutical Industries Limited has a one year low of $10.85 and a one year high of $39.08. The firm has a market cap of $14,061.44, a price-to-earnings ratio of 3.20 and a beta of 0.52. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be issued a $0.085 dividend. This represents a $0.34 annualized dividend and a dividend yield of 2.46%. The ex-dividend date of this dividend is Monday, November 27th. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is -15.80%.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.